Research programme: anti-FLT3 radioimmunoconjugates -Eli Lilly

Drug Profile

Research programme: anti-FLT3 radioimmunoconjugates -Eli Lilly

Alternative Names: 177Lu-EB10; Flt-3 MAb

Latest Information Update: 07 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly
  • Class Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 28 Apr 2006 Preclinical trials in Haematological malignancies in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top